Table 2 Clinical assessment result changes from baseline to week 120 in the rituximab and DMARD treatment groups

Global disease activity VAS (mm)

88.7 ± 3.3

88.7 ± 3.3

77 ± 2.2†

72.4 ± 4.0‡

71 ± 3.2‡

68.5 ± 4.6‡

63 ± 3.9*

60.0 ± 4.6*

54 ± 3.5*

51.8 ± 3.0*

50.5 ± 3.7*

47.1 ± 3.5*

52.1 ± 4.8*

45.3 ± 3.9*

Pain VAS (mm)

70.1 ± 9.0

71.1 ± 8.7

59.8 ± 7.8†

55 ± 7.4†

56.7 ± 7.8‡

53.5 ± 7.5‡

51.3 ± 7.5*

44.1 ± 8.5*

41 ± 7.6*

36.3 ± 7.9*

40.5 ± 7.5*

33.1 ± 7.0*

39.3 ± 8.3*

29.8 ± 7.8*

Fatigue VAS (mm)

85.1 ± 4.6

83.8 ± 4.1

73 ± 4.5†

63.1 ± 4.3‡

63.1 ± 4.7‡

58.7 ± 5.1‡

60.1 ± 4.4*

56.2 ± 5.5*

52.2 ± 4.0*

47.8 ± 4.7*

50.5 ± 3.8*

42.5 ± 4.1*

51.8 ± 4.5*

41.1 ± 4.2*

Dryness VAS (mm)

71.0 ± 8.3

72 ± 8.5

61.1 ± 8.3

55.3 ± 7.6‡

58 ± 8.2†

52.2 ± 7.6‡

56.3 ± 8.4‡

44.1 ± 8.5*

53.8 ± 11.0*

36.3 ± 7.9*

51.8 ± 10.4*

30.7 ± 8.0*

51.8 ± 11.1*

25.1 ± 7.7*

Physician GA VAS (mm)

89.7 ± 3.0

87.1 ± 2.3

78.6 ± 2.6†

69.1 ± 3.0†

73.1 ± 3.4‡

65 ± 4.4‡

65.0 ± 3.9*

56.6 ± 4.3*

56.6 ± 3.8*

50.3 ± 3.0*

54.7 ± 4.5*

45.8 ± 3.3*

56.1 ± 4.9*

44.0 ± 3.7*

Unstimulated salivary flow (ml/minute)

0.08 ± 0.03

0.08 ± 0.04

0.1 ± 0.04

0.2 ± 0.04‡

0.1 ± 0.04

0.3 ± 0.04‡

0.1 ± 0.07

0.4 ± 0.02*

0.1 ± 0.06

0.3 ± 0.001*

0.1 ± 0.08

0.4 ± 0.04*

0.1 ± 0.08

0.4 ± 0.04*

Schirmer I test (mm/5 minutes)

3.8 ± 0.6

3.8 ± 0.6

4 ± 0.5

5.5 ± 0.4‡

4.5 ± 0.7

6.0 ± 0.5†

5.1 ± 0.8

6.3 ± 0.6‡

5.1 ± 0.7

7.0 ± 0.7*

5.3 ± 0.7†

7.0 ± 0.7*

5.5 ± 0.8‡

7.3 ± 0.8*

ESSDAI

19.8 ± 3.1

20.3 ± 2.9

17.6 ± 3.2

14.2a ± 2.8

14.2 ± 3.0‡

9.8 ± 2.0‡

12.3 ± 2.0*

9.4 ± 1.6‡

10.2 ± 2.0*

5.7 ± 1.0*

9.7 ± 2.0*

5.7 ± 1.0*

8.8 ± 1.7*

5.2 ± 0.9*